Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis

Liver International

Volumn 33, Issue 8, 2013, Pages 1166-1174

  Cash, William J ^a   O'Neill, Stephen ^a   O'Donnell, Mark E ^a   Mccance, David R ^a   Young, Ian S ^a,b   Mceneny, Jane ^b   Mcdougall, Neil I ^a   Callender, Michael E ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antioxidant; Endothelial function; Primary biliary cirrhosis; Randomized controlled trial; Safety; Simvastatin

Indexed keywords

ASCORBIC ACID; CHOLESTEROL; GLUCOSE; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL COMPLIANCE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LIVER FUNCTION; MALE; MYALGIA; PRIMARY BILIARY CIRRHOSIS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SINGLE BLIND PROCEDURE; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

ANTIOXIDANT; ENDOTHELIAL FUNCTION; PRIMARY BILIARY CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL; SAFETY; SIMVASTATIN;

ASCORBIC ACID; BIOLOGICAL MARKERS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; LIPID PEROXIDES; LIPOPROTEINS, LDL; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NORTHERN IRELAND; PULSE WAVE ANALYSIS; SIMVASTATIN; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84881550708     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12191     Document Type: Article

References (41)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
2. Cash WJ, McCance DR, Young IS, et al. Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. Hepatol Res 2010; 40: 1098-106.
3. Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992; 15: 858-62.
4. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51: 265-9.
5. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
6. Reriani MK, Dunlay SM, Gupta B, et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 2011; 18: 704-16.
7. Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42: 437-41.
8. Ritzel U, Leonhardt U, Nather M, et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36: 454-8.
9. Kurihara T, Akimoto M, Abe K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993; 15: 890-8.
10. Kamisako T, Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 1995; 90: 1187-8.
11. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004; 71: 58-62.
12. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Overview on the mechanisms of drug-induced liver cell death. Ann Hepatol 2002; 1: 162-8.
13. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2011; 56: 374-80.
14. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-91.
15. Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-83.
16. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-12.
17. Vuilleumier JP, Keller HE, Keck E. Clinical chemical methods for the routine assessment of the vitamin status in human populations Part III: the apoenzyme stimulation tests for vitamin B1, B2 and B6 adapted to the Cobas-Bio analyzer. Int J Vitam Nutr Res 1990; 60: 126-35.
18. Craft NE. WSA, Soares JHOptimization of an isocratic high-performance liquid chromatographic separation of carotenoids. J Chromatogr 1992; 589: 171-6.
19. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002; 22: 147-52.
20. O'Rourke MF, Gallagher DE. Pulse wave analysis. J Hypertens Suppl 1996; 14: S147-57.
21. Cockcroft JR, Wilkinson IB. Arterial stiffness and pulse contour analysis: an age old concept revisited. Clin Sci (Lond) 2002; 103: 379-80.
22. Marasini B, Pipia C, DeValle G, et al. Vascular impairment in patients with primary biliary cirrhosis. Int J Microcirc Clin Exp 1995; 15: 75-9.
23. Polzien F, Ramadori G. Increased intercellular adhesion molecule-1 serum concentration in cholestasis. J Hepatol 1996; 25: 877-86.
24. Aboutwerat A, Pemberton PW, Smith A, et al. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta 2003; 1637: 142-50.
25. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-34.
26. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541-7.
27. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
28. Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 2008; 138: 415-9.
29. Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46: 776-84.
30. Stanca CM, Bach N, Allina J, et al. Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis. Dig Dis Sci 2008; 53: 1988-93.
31. Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55: 2086-8.
32. Cangemi R, Loffredo L, Carnevale R, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J 2008; 29: 54-62.
33. Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 2011; 7: 333-43.
34. Liu CS, Lii CK, Chang LL, et al. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients. Nutr Res 2010; 30: 118-24.
35. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007; 194: e123-30.
36. McCall DO, McGartland CP, Woodside JV, et al. The relationship between microvascular endothelial function and carotid-radial pulse wave velocity in patients with mild hypertension. Clin Exp Hypertens 2010; 32: 474-9.
37. Ott C, Schneider MP, Schlaich MP, Schmieder RE. Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvasc Res 2012; 84: 60-4.
38. Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-22.
39. Doycheva I, Chen C, Pan JJ, Levy C. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol 2011; 3: 93-8.
40. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194: 293-9.
41. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453-63.